{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T18:15:12Z","timestamp":1794507312797,"version":"4.9.1"},"reference-count":50,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,3]]},"DOI":"10.1097\/md.0000000000003060","type":"journal-article","created":{"date-parts":[[2016,4,22]],"date-time":"2016-04-22T13:04:49Z","timestamp":1461330289000},"page":"e3060","source":"Crossref","is-referenced-by-count":28,"title":["Comparative Effectiveness of Biologic Therapy Regimens for Ankylosing Spondylitis"],"prefix":"10.1097","volume":"95","author":[{"given":"Chao","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"XiaoLin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"XueSong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"XinLong","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-37-20210226","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1016\/S0140-6736(07)60635-7","article-title":"Ankylosing spondylitis","volume":"369","author":"Braun","year":"2007","journal-title":"Lancet"},{"key":"R2-37-20210226","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1136\/ard.2004.029728","article-title":"Association between radiographic damage of the spine and spinal mobility for individual patients with ankylosing spondylitis: can assessment of spinal mobility be a proxy for radiographic evaluation","volume":"64","author":"Wanders","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"R3-37-20210226","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1517\/13543784.2014.899351","article-title":"Tumor necrosis factor alpha antagonists in the treatment of axial spondyloarthritis","volume":"23","author":"Braun","year":"2014","journal-title":"Expert Opin Investig Drugs"},{"key":"R4-37-20210226","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1136\/ard.2011.151563","article-title":"2010 Update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis","volume":"70","author":"van der Heijde","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"R5-37-20210226","doi-asserted-by":"crossref","first-page":"665","DOI":"10.3899\/jrheum.141001","article-title":"2014 update of the Canadian Rheumatology Association\/Spondyloarthritis Research Consortium of Canada treatment recommendations for the management of spondyloarthritis. Part II: specific management recommendations","volume":"42","author":"Rohekar","year":"2015","journal-title":"J Rheumatol"},{"key":"R6-37-20210226","doi-asserted-by":"crossref","first-page":"654","DOI":"10.3899\/jrheum.141000","article-title":"2014 update of the Canadian Rheumatology Association\/Spondyloarthritis Research Consortium of Canada treatment recommendations for the management of spondyloarthritis. Part I: principles of the management of spondyloarthritis in Canada","volume":"42","author":"Rohekar","year":"2015","journal-title":"J Rheumatol"},{"key":"R7-37-20210226","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/j.berh.2014.10.019","article-title":"Treatment of spondyloarthritis beyond TNF-alpha blockade","volume":"28","author":"Van den Bosch","year":"2014","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"R8-37-20210226","doi-asserted-by":"crossref","first-page":"669","DOI":"10.2217\/imt.15.28","article-title":"Biologics in spondyloarthritis: TNFalpha inhibitors and other agents","volume":"7","author":"Toussirot","year":"2015","journal-title":"Immunotherapy"},{"key":"R9-37-20210226","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1586\/1744666X.2015.1039514","article-title":"Treating to target in axial spondyloarthritis: defining the target and the arrow","volume":"11","author":"Wendling","year":"2015","journal-title":"Expert Rev Clin Immunol"},{"key":"R10-37-20210226","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1097\/BOR.0000000000000069","article-title":"The interleukin-23\/interleukin-17 immune axis as a promising new target in the treatment of spondyloarthritis","volume":"26","author":"Yeremenko","year":"2014","journal-title":"Curr Opin Rheumatol"},{"key":"R11-37-20210226","doi-asserted-by":"crossref","first-page":"259","DOI":"10.3109\/08916934.2014.976630","article-title":"Interleukin-17 is a critical target for the treatment of ankylosing enthesitis and psoriasis-like dermatitis in mice","volume":"48","author":"Ebihara","year":"2015","journal-title":"Autoimmunity"},{"key":"R12-37-20210226","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1111\/cei.12670","article-title":"The IL23\/IL17 axis in Ankylosing Spondylitis: new advances and potentials for treatment","volume":"183","author":"Jethwa","year":"2016","journal-title":"Clin Exp Immunol"},{"key":"R13-37-20210226","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1002\/hep.27999","article-title":"Comparative effectiveness of pharmacological interventions for non-alcoholic steatohepatitis: a systematic review and network meta-analysis","volume":"62","author":"Singh","year":"2015","journal-title":"Hepatology"},{"key":"R14-37-20210226","doi-asserted-by":"crossref","first-page":"777","DOI":"10.7326\/M14-2385","article-title":"The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations","volume":"162","author":"Hutton","year":"2015","journal-title":"Ann Intern Med"},{"key":"R15-37-20210226","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1002\/art.1780270401","article-title":"Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria","volume":"27","author":"van der Linden","year":"1984","journal-title":"Arthritis Rheum"},{"key":"R16-37-20210226","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1186\/2046-4053-3-110","article-title":"A Microsoft-Excel-based tool for running and critically appraising network meta-analyses: an overview and application of NetMetaXL","volume":"3","author":"Brown","year":"2014","journal-title":"Syst Rev"},{"key":"R18-37-20210226","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1002\/art.21913","article-title":"Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial","volume":"54","author":"van der Heijde","year":"2006","journal-title":"Arthritis Rheum"},{"key":"R19-37-20210226","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1136\/annrheumdis-2012-202533","article-title":"Efficacy and safety of adalimumab in Chinese adults with active ankylosing spondylitis: results of a randomised, controlled trial","volume":"73","author":"Huang","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"R20-37-20210226","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.dss.2012.10.005","article-title":"ADDIS: a decision support system for evidence-based medicine","volume":"55","author":"Van Valkenhoef","year":"2013","journal-title":"Decis Support Syst"},{"key":"R21-37-20210226","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1080\/10618600.1998.10474787","article-title":"General methods for monitoring convergence of iterative simulations","volume":"7","author":"Brooks","year":"1998","journal-title":"J Comput Graph Stat"},{"key":"R22-37-20210226","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1198\/016214505000001302","article-title":"Assessing evidence inconsistency in mixed treatment comparisons","volume":"101","author":"Lu","year":"2006","journal-title":"J Am Stat Assoc"},{"key":"R23-37-20210226","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1002\/sim.3767","article-title":"Checking consistency in mixed treatment comparison meta-analysis","volume":"29","author":"Dias","year":"2010","journal-title":"Stat Med"},{"key":"R24-37-20210226","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.jclinepi.2010.07.015","article-title":"GRADE guidelines: 3. Rating the quality of evidence","volume":"64","author":"Balshem","year":"2011","journal-title":"J Clin Epidemiol"},{"key":"R25-37-20210226","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.jclinepi.2010.04.026","article-title":"GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables","volume":"64","author":"Guyatt","year":"2011","journal-title":"J Clin Epidemiol"},{"key":"R26-37-20210226","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/j.jclinepi.2011.01.012","article-title":"GRADE guidelines 6. Rating the quality of evidence\u2014imprecision","volume":"64","author":"Guyatt","year":"2011","journal-title":"J Clin Epidemiol"},{"key":"R27-37-20210226","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1016\/j.jclinepi.2011.03.017","article-title":"GRADE guidelines: 7. Rating the quality of evidence\u2014inconsistency","volume":"64","author":"Guyatt","year":"2011","journal-title":"J Clin Epidemiol"},{"key":"R28-37-20210226","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1016\/j.jclinepi.2011.04.014","article-title":"GRADE guidelines: 8. Rating the quality of evidence\u2014indirectness","volume":"64","author":"Guyatt","year":"2011","journal-title":"J Clin Epidemiol"},{"key":"R29-37-20210226","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1016\/j.jclinepi.2011.01.011","article-title":"GRADE guidelines: 5. Rating the quality of evidence\u2014publication bias","volume":"64","author":"Guyatt","year":"2011","journal-title":"J Clin Epidemiol"},{"key":"R30-37-20210226","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.jclinepi.2010.07.017","article-title":"GRADE guidelines: 4. Rating the quality of evidence\u2014study limitations (risk of bias)","volume":"64","author":"Guyatt","year":"2011","journal-title":"J Clin Epidemiol"},{"key":"R31-37-20210226","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.jclinepi.2012.01.006","article-title":"GRADE guidelines: 11. Making an overall rating of confidence in effect estimates for a single outcome and for all outcomes","volume":"66","author":"Guyatt","year":"2013","journal-title":"J Clin Epidemiol"},{"key":"R32-37-20210226","doi-asserted-by":"crossref","first-page":"3230","DOI":"10.1002\/art.11325","article-title":"Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial","volume":"48","author":"Davis","year":"2003","journal-title":"Arthritis Rheum"},{"key":"R33-37-20210226","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1136\/ard.2004.020875","article-title":"Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis","volume":"63","author":"Calin","year":"2004","journal-title":"Ann Rheum Dis"},{"key":"R34-37-20210226","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1002\/art.20852","article-title":"Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT)","volume":"52","author":"van der Heijde","year":"2005","journal-title":"Arthritis Rheum"},{"key":"R35-37-20210226","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1136\/ard.2006.056747","article-title":"Etanercept 50\u200amg once weekly is as effective as 25\u200amg twice weekly in patients with ankylosing spondylitis","volume":"65","author":"van der Heijde","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"R36-37-20210226","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1007\/s00296-009-1157-3","article-title":"A 2-year comparative open label randomized study of efficacy and safety of etanercept and infliximab in patients with ankylosing spondylitis","volume":"30","author":"Giardina","year":"2010","journal-title":"Rheumatol Int"},{"key":"R37-37-20210226","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.3899\/jrheum.091042","article-title":"A double-blind, placebo-controlled trial of low dose infliximab in ankylosing spondylitis","volume":"37","author":"Inman","year":"2010","journal-title":"J Rheumatol"},{"key":"R38-37-20210226","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1093\/rheumatology\/ker083","article-title":"High-dose etanercept in ankylosing spondylitis: results of a 12-week randomized, double blind, controlled multicentre study (LOADET study)","volume":"50","author":"Navarro-Sarabia","year":"2011","journal-title":"Rheumatology (Oxford"},{"key":"R39-37-20210226","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1016\/S0140-6736(13)61134-4","article-title":"Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial","volume":"382","author":"Baeten","year":"2013","journal-title":"Lancet"},{"key":"R40-37-20210226","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1093\/rheumatology\/keu132","article-title":"Safety and efficacy of golimumab in Chinese patients with active ankylosing spondylitis: 1-year results of a multicentre, randomized, double-blind, placebo-controlled phase III trial","volume":"53","author":"Bao","year":"2014","journal-title":"Rheumatology (Oxford"},{"key":"R41-37-20210226","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1136\/annrheumdis-2013-203559","article-title":"Assessment of short-term symptomatic efficacy of tocilizumab in ankylosing spondylitis: results of randomised, placebo-controlled trials","volume":"73","author":"Sieper","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"R42-37-20210226","doi-asserted-by":"crossref","first-page":"3402","DOI":"10.1002\/art.23969","article-title":"Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial","volume":"58","author":"Inman","year":"2008","journal-title":"Arthritis Rheum"},{"key":"R43-37-20210226","doi-asserted-by":"crossref","first-page":"473","DOI":"10.3111\/13696998.2012.660255","article-title":"Indirect comparison of the effects of anti-TNF biological agents in patients with ankylosing spondylitis by means of a mixed treatment comparison performed on efficacy data from published randomised, controlled trials","volume":"15","author":"Migliore","year":"2012","journal-title":"J Med Econ"},{"key":"R44-37-20210226","first-page":"717","article-title":"Indirect comparison of anti-TNF-alpha agents for active ankylosing spondylitis: mixed treatment comparison of randomized controlled trials","volume":"31","author":"Shu","year":"2013","journal-title":"Clin Exp Rheumatol"},{"key":"R45-37-20210226","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s40261-014-0246-6","article-title":"Indirect comparison between subcutaneous biologic agents in ankylosing spondylitis","volume":"35","author":"Migliore","year":"2015","journal-title":"Clin Drug Investig"},{"key":"R46-37-20210226","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1016\/S0140-6736(08)60726-6","article-title":"Efficacy and safety of ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)","volume":"371","author":"Papp","year":"2008","journal-title":"Lancet"},{"key":"R47-37-20210226","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1016\/S0140-6736(08)60725-4","article-title":"Efficacy and safety of ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)","volume":"371","author":"Leonardi","year":"2008","journal-title":"Lancet"},{"key":"R48-37-20210226","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/S0140-6736(13)60594-2","article-title":"Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial","volume":"382","author":"McInnes","year":"2013","journal-title":"Lancet"},{"key":"R49-37-20210226","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1136\/annrheumdis-2013-204655","article-title":"Efficacy and safety of the anti-IL-12\/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial","volume":"73","author":"Ritchlin","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"R50-37-20210226","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1136\/annrheumdis-2013-204248","article-title":"Ustekinumab for the treatment of patients with active ankylosing spondylitis: results of a 28-week, prospective, open-label, proof-of-concept study (TOPAS)","volume":"73","author":"Poddubnyy","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"R51-37-20210226","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta11280","article-title":"Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation","volume":"11","author":"McLeod","year":"2007","journal-title":"Health Technol Assess"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000003060","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,15]],"date-time":"2024-06-15T22:39:29Z","timestamp":1718491169000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00005792-201603150-00037"}},"subtitle":["A Systematic Review and a Network Meta-Analysis"],"short-title":[],"issued":{"date-parts":[[2016,3]]},"references-count":50,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000003060","relation":{},"ISSN":["0025-7974"],"issn-type":[{"value":"0025-7974","type":"print"}],"subject":[],"published":{"date-parts":[[2016,3]]}}}